We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 21, 2021

Assessment of Pembrolizumab for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
JAMA Oncol 2021 Jun 01;7(6)895-902, J Chao, CS Fuchs, K Shitara, J Tabernero, K Muro, E Van Cutsem, YJ Bang, F De Vita, G Landers, CJ Yen, I Chau, A Elme, J Lee, M Özgüroglu, D Catenacci, HH Yoon, E Chen, D Adelberg, CS Shih, S Shah, P Bhagia, ZA Wainberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading